Literature DB >> 31031885

Stroke prevention: Learning from the master (and COMMANDER).

Gaetano Santulli1.   

Abstract

Adding rivaroxaban to standard therapy in patients with heart failure and no atrial fibrillation did not show any beneficial effect on death risk.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 31031885      PMCID： PMC6485931          DOI： 10.1126/scitranslmed.aav0340

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  1 in total

1.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Authors:  Faiez Zannad; Stefan D Anker; William M Byra; John G F Cleland; Min Fu; Mihai Gheorghiade; Carolyn S P Lam; Mandeep R Mehra; James D Neaton; Christopher C Nessel; Theodore E Spiro; Dirk J van Veldhuisen; Barry Greenberg
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.